Macitentan/tadalafil

Macitentan/tadalafil, sold under the brand name Opsynvi, is a fixed dose combination medication used for the treatment of pulmonary arterial hypertension. It contains macitentan, an endothelin receptor antagonist (ERA); and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor.

Macitentan/tadalafil was approved for medical use in Canada in October 2021, and in the United States in March 2024.

Medical uses
Macitentan/tadalafil is indicated for the chronic treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adults of WHO functional class (FC) II-III.

Adverse effects
Macitentan/tadalafil may cause harm to the fetus.